Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density.

Objective: To assess the efficacy, safety, and effect on bone mineral density of a 3-month course of retreatment with intranasal nafarelin acetate for recurrent symptoms of endometriosis.

Design: Multicenter, open-label, nonrandomized clinical trial.

Setting: Eleven hospital-based and private practices.

Prediction of pregnancy in infertile women based on the American Society for Reproductive Medicine's revised classification of endometriosis.

Objective: To estimate the empirical relationship between the revised American Society for Reproductive Medicine's classification of endometriosis and pregnancy rates after treatment.

Design: Retrospective analysis.

Patient(s): Patients seen by four practicing physicians.

Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain.

Objectives: To determine the effectiveness of a 3-month course of nafarelin and, furthermore, to determine the long-term efficacy in patients treated for 3 and 6 months with nafarelin for symptoms associated with endometriosis.

Design: Double-blind, prospective, multicenter, clinical trial.

Setting: Fifteen reproductive endocrine clinics throughout the United States.

Nafarelin therapy in endometriosis: long-term effects on bone mineral density.

Objective: The study intent was to examine long-term effects on bone mass of 3 or 6 months of nafarelin therapy for endometriosis.

Study Design: Women with established endometriosis (N = 173) were randomized to receive nafarelin (200 micrograms intranasally twice a day) for either 3 or 6 months in a double-blind fashion. Bone mineral density was measured by dual energy x-ray absorptiometry at lumbar spine and proximal femoral sites for 18 months.